Evidence map›Paper›PMID 41591595›Full record

SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026

Timing of anticoagulation therapy in patients with acute ischemic stroke and atrial fibrillation: a GRADE-based expert opinion recommendation.

Emanuele Spina, Michele Romoli, Maria Giulia Mosconi, Marina Padroni, Isabella Canavero, Marina Mannino, Maria Luisa Zedde, Stefano Ricci, Maurizio Paciaroni

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emanuele Spina *UOC Neurology and Stroke Unit, AORN "A. Cardarelli", Naples, Italy. ema.spinaes@gmail.com.ORCID http://orcid.org/0000-0001-5123-2459
Michele Romoli *Department of Neuroscience, Neurology and Stroke Unit Cesena and Forlì, AUSL Romagna, Cesena and Forlì, Italy.
Maria Giulia MosconiDepartment of Internal and Cardiovascular Medicine-Stroke Unit, Santa Maria della Misericordia Hospital, Perugia, Italy.
Marina PadroniNeurosciences and Rehabilitation Department, Neurology Unit, Ferrara University Hospital, Ferrara, Italy.
Isabella CanaveroCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Marina ManninoDepartment of Neurology, AOOR Villa Sofia-Cervello, Palermo, Italy.
Maria Luisa ZeddeNeurology Unit, Stroke Unit, Azienda Unità Sanitaria Locale-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.
Stefano RicciCoordinatore Comitato Scientifico ISA-AII, Città di Castello, Italy.
Maurizio PaciaroniNeurosciences and Rehabilitation Department, Neurology Unit, Ferrara University Hospital, Ferrara, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe optimal timing for initiating direct oral anticoagulants (DOACs) after acute ischemic stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (NVAF) remains uncertain.

objectiveTo determine whether early initiation of DOACs is superior to delayed initiation in preventing new vascular events.

methodsThis guideline was developed using the GRADE approach and includes a systematic review and meta-analysis of four randomized controlled trials (TIMING, ELAN, OPTIMAS, START) enrolling 6,664 patients. Outcomes were selected via Delphi consensus. Meta-analyses used random-effects models, with certainty of evidence rated per GRADE methodology.

resultsEarly DOAC initiation was associated with a trend toward fewer recurrent ischemic events (RR 0.77, 95% CI 0.52-1.14) and thromboembolic events (RR 0.73, 95% CI 0.50-1.06), with no increase in symptomatic intracranial hemorrhage (RR 0.93, 95% CI 0.44-1.97) or major extracranial bleeding (RR 0.84, 95% CI 0.42-1.69). Certainty of evidence was low due to imprecision. An individual patient data meta-analysis from CATALYST collaboration further supported early treatment in patients with minor to moderate stroke. RECOMMENDATIONS: We recommend early DOAC initiation within 4 days in patients with minor to moderate stroke to prevent new vascular events. Early DOAC initiation over delayed treatment is indicated in patients with severe acute ischemic stroke to prevent new vascular events.

conclusionEarly DOAC initiation appears safe and potentially more effective than delayed treatment, supporting a shift toward earlier anticoagulation in selected patients with NVAF and recent ischemic stroke.

Indexed as

AnticoagulantsAtrial FibrillationIschemic StrokeHumansTime FactorsAnticoagulantsAcute ischemic strokeDOACEarly anticoagulationNon-valvular atrial fibrillationSecondary prevention

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.